Condition

Mantle Cell Lymphoma (MCL) clinical trials and research

• 21Clinical trials
• 16Countries

Newest Mantle Cell Lymphoma (MCL) clinical trials

All recruiting trials (21)

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• Orelabrutinib with Obinutuzumab and Short-Course Venetoclax in Treatment-Naïve Mantle Cell Lymphoma

  This trial tests whether a combo of orelabrutinib, obinutuzumab, and a short course of venetoclax is safe and effective for adults with newly diagnosed mantle cell lymphoma.

  Recruiting at 2 sites Phase 2 The First Affiliated Hospital with Nanjing Medical University · Changzhou, Jiangsu and 1 other locations · NCT07719556

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• Pirtobrutinib plus rituximab for adults with newly diagnosed indolent mantle cell lymphoma

  This trial will test whether combining pirtobrutinib with rituximab is effective and safe for adults newly diagnosed with indolent mantle cell lymphoma.

  Recruiting at 12 sites Phase 2 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Lisbon, Lisbon District and 15 other locations · NCT07285590

• Orelabrutinib with lisaftoclax and rituximab for untreated high-risk mantle cell lymphoma

  This trial will try combining orelabrutinib, lisaftoclax, and rituximab in people with untreated, high-risk mantle cell lymphoma to see if it increases complete remissions and delays progression.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07272499

• Pomalidomide with orelabrutinib and zuberitamab for newly diagnosed mantle cell lymphoma

  This study tests whether adding pomalidomide to orelabrutinib and zuberitamab helps people with untreated mantle cell lymphoma become minimal residual disease (MRD) negative after six treatment cycles.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07257510

• Orelabrutinib with rituximab and optional autologous stem cell transplant for mantle cell lymphoma

  This phase 2 trial tests whether adding the oral BTK inhibitor orelabrutinib to rituximab, with optional autologous stem cell transplant and orelabrutinib maintenance, works and is safe for people with newly diagnosed non-high-risk mantle cell lymphoma.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07199296

• Safety testing of LTZ-301 in adults with relapsed or refractory B‑cell non-Hodgkin lymphoma

  This trial will test whether LTZ-301 is safe and how it behaves in adults whose B‑cell non-Hodgkin lymphoma has come back or not responded after at least two prior treatments.

  Recruiting at 6 sites Phase 1 LTZ Therapeutics, Inc. · Duarte, California and 5 other locations · NCT07121946

• Relmacabtagene autoleucel plus sintilimab for relapsed or refractory CD19‑positive B‑cell lymphoma

  This trial will test whether giving relmacabtagene autoleucel followed by the PD‑1 drug sintilimab helps adults with relapsed or refractory CD19‑positive large B‑cell, follicular, or mantle cell lymphoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou and 2 other locations · NCT07077512

• Testing EXS73565 for patients with relapsed or refractory B-cell cancers

  This study is testing a new oral medication called EXS73565 to see if it can help adults with B-cell cancers that haven't responded to other treatments.

  Recruiting at 17 sites Phase 1 Exscientia AI Limited · Tbilisi and 16 other locations · NCT06980116

• Acalabrutinib with rituximab for untreated mantle cell lymphoma in older adults and lower-risk younger patients

  This trial tests whether combining acalabrutinib and rituximab can produce complete remissions at 12 months in people with untreated mantle cell lymphoma who are elderly or younger with low- to intermediate-risk disease.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06846489

• Long-term safety and effectiveness of lisocabtagene maraleucel for Mantle Cell Lymphoma

  This study looks at how safe and effective the treatment lisocabtagene maraleucel is for people with relapsed or refractory Mantle Cell Lymphoma over a long period of time.

  Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Milwaukee, Wisconsin · NCT06788652

• Combining Orelabrutinib with Bendamustine and Rituximab for treating Mantle Cell Lymphoma

  This study is testing if adding Orelabrutinib to the standard treatment of Bendamustine and Rituximab can help people with intermediate- to high-risk mantle cell lymphoma who can't have a transplant feel better and live longer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT06496308

• Treatment for relapsed B cell lymphoma using CAR-NK and CAR-T cells

  This study is testing a new treatment for people with relapsed B cell lymphoma that uses two types of immune cells, CAR-NK and CAR-T, to see if it helps them feel better.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06464861

• Registry platform for patients with blood cancers in Germany

  This study is setting up a national registry to collect information from patients with blood cancers in Germany to see how well different treatments work and what patients need.

  Recruiting iOMEDICO AG · Freiburg im Breisgau · NCT06043011

• Evaluating NX-5948 for advanced B-cell cancers

  This study is testing a new drug called NX-5948 to see if it can safely help adults with tough-to-treat B-cell cancers feel better.

  Recruiting at 53 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 61 other locations · NCT05131022

• Testing a new CAR T cell therapy for adolescents and adults with relapsed B-cell Non-Hodgkin Lymphoma

  This study is testing a new CAR T cell therapy to see if it can help adolescents and adults with relapsed B-cell Non-Hodgkin Lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT05098613

• Evaluating NX-2127 for adults with advanced B-cell cancers

  This study is testing a new treatment called NX-2127 to see if it can help adults with advanced B-cell cancers feel better and fight their disease.

  Recruiting at 7 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 15 other locations · NCT04830137

• CAR-T cell therapy for relapsed or refractory DLBCL

  This study is testing a new CAR-T cell therapy to see if it can help people with tough-to-treat diffuse large B cell lymphoma feel better after other treatments haven’t worked.

  Recruiting at 30 sites Phase 2 Miltenyi Biomedicine GmbH · Birmingham, Alabama and 31 other locations · NCT04792489

• CAR-T cell therapy for patients with relapsed B cell cancers

  This study is testing a new CAR-T cell therapy for adults with relapsed B cell cancers to see how well it works and if different manufacturing methods make a difference in treatment outcomes.

  Recruiting Phase 1/2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04186520

• Real-world data collection for lymphoma and patient survival

  This study is trying to gather real-life information from lymphoma patients to see how different factors affect their treatment success and long-term survival.

  Recruiting at 37 sites Hospices Civils de Lyon · Arras and 36 other locations · NCT03869619

Related topics

Quick answers

How many Mantle Cell Lymphoma (MCL) clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 16 countries. The most sites are in China (10 trials), United States (7 trials), Spain (3 trials), France (2 trials), Poland (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1: 6, Phase 1/2: 3, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →